Every one of those 1 sits in a single category, clinical-trial. Of the tracked stories, 1 of 1 also mention DT120, the most common co-covered peer. The average consequence score is 6, matching the 6 beat baseline for this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Jefferies
Every one of those 1 sits in a single category, clinical-trial. Of the tracked stories, 1 of 1 also mention DT120, the most common co-covered peer. The average consequence score is 6, matching the 6 beat baseline for this window. Source depth averages 2 original sources per story, versus 2.4 across the same-window beat baseline. Jefferies appears in 1 tracked Biotech story from February 19, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 27 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Jefferies. Shared-story counts are live from our verified record — not editorial picks.
Jefferies analysts have issued a high-conviction outlook on Definium Therapeutics' lead candidate, DT120, assigning a 65-75% probability that the drug will demonstrate best-in-class efficacy in its ongoing Phase III trials. This projection positions the company as a potential disruptor in its therapeutic category, significantly raising market expectations ahead of upcoming data readouts.
